NCT03903016View on ClinicalTrials.gov

A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

August 19, 2019

Study Completion Date

August 19, 2019

Conditions
Type 1 Diabetes
Interventions
DRUG

Insulin Lispro SAR342434

Pharmaceutical form:solution for injection Route of administration: subcutaneous

DRUG

Insulin Lispro SAR342434

Pharmaceutical form:solution for injection Route of administration: subcutaneous

Trial Locations (1)

41460

Investigational Site Number 2760001, Neuss

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03903016 - A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter